EXPLORE THE SCIENCE
TL;DR: A 2026 open-label feasibility trial in IBRO Neuroscience Reports tested an AI-guided variable levodopa schedule in 5 people with Parkinson’s disease and found 4 patients improved on UPDRS, but the study was far too small and uncontrolled to prove effica…
Read article
TL;DR: A 2026 Neurological Sciences study followed 216 early Parkinson’s patients for 2 years after levodopa started and found that several non-motor symptom differences between men and women persisted or emerged despite adjustment for baseline scores and levo…
Read article
TL;DR: A 2026 medRxiv preprint found that alpha-synuclein seed-positive Parkinson’s patients had slower ON-medication motor progression, measured while usual Parkinson’s medication was active, and more sustained levodopa responsiveness than matched seed-negati…
Read article
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons. Dopamine plays an important role in PD development. Here are some key facts: Dopamine is a chemical messenger in the brain involved in movement, m…
Read article